靶向酪氨酸激酶信号通路治疗免疫介导性肾小球肾炎:从基础到临床及未来
免疫介导性肾小球肾炎(GN)现有非选择性免疫抑制治疗副作用大。临床前和临床研究显示多种酪氨酸激酶信号通路异常激活参与GN发病。本综述讨论GN治疗未满足需求、酪氨酸激酶抑制剂(TKIs)研发进展,并提出加速转化研究以评估选择性抑制酪氨酸激酶是否提供更安全有效的治疗选择。
要点
- SYK、BTK、PDGFR、EGFR、DDR1等酪氨酸激酶在抗GBM病、ANCA相关GN和狼疮肾炎中异常激活。
- fostamatinib(口服SYK抑制剂)正在高危IgA肾病患者的II期临床试验中评估疗效和安全性。
- 已获批抗癌的TKIs具有长期安全性数据,支持其在GN中开展临床试验。
核心结论
- 选择性抑制酪氨酸激酶可能为免疫介导性GN提供更安全有效的治疗选择,需加速转化研究验证。
研究设计与样本
- 综述,总结临床前和临床研究证据及TKIs在GN中的研发阶段。
主要发现
- 抗GBM病中已证实SYK、BTK、PDGFR、EGFR和DDR1激活;ANCA相关GN涉及SYK;狼疮肾炎涉及SYK、BTK、PDGFR、EGFR、DDR1和Janus激酶。
- IgA肾病缺乏代表性动物模型,基于体外和人类肾活检结果,fostamatinib(口服SYK抑制剂)在高危IgA肾病患者中的II期临床试验正在进行。
临床怎么用
- 关注TKIs在免疫介导性GN中的临床试验进展,尤其是fostamatinib用于高危IgA肾病。
局限性
- IgA肾病缺乏代表性动物模型,TKIs在GN中的疗效和安全性尚未确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glomerulonephritis (GN) affects patients of all ages and is an important cause of morbidity and mortality. Non-selective immunosuppressive drugs have been used in immune-mediated GN but often result in systemic side effects and occasionally fatal infective complications. There is increasing evidence from both preclinical and clinical studies that abnormal activation of receptor and non-receptor tyrosine kinase signalling pathways are implicated in the pathogenesis of immune-mediated GN. Activation of spleen tyrosine kinase (SYK), Bruton's tyrosine kinase (BTK), platelet-derived growth factor receptor (PDGFR), epidermal growth factor receptor (EGFR) and discoidin domain receptor 1 (DDR1) have been demonstrated in anti-GBM disease. SYK is implicated in the pathogenesis of ANCA-associated GN. SYK, BTK, PDGFR, EFGR, DDR1 and Janus kinase are implicated in the pathogenesis of lupus nephritis. A representative animal model of IgA nephropathy (IgAN) is lacking. Based on the results from in vitro and human renal biopsy study results, a phase II clinical trial is ongoing to evaluate the efficacy and safety of fostamatinib (an oral SYK inhibitor) in high-risk IgAN patient. Various tyrosine kinase inhibitors (TKIs) have been approved for cancer treatment. Clinical trials of TKIs in GN may be justified given their long-term safety data. In this review we will discuss the current unmet medical needs in GN treatment and research as well as the current stage of development of TKIs in GN treatment and propose an accelerated translational research approach to investigate whether selective inhibition of tyrosine kinase provides a safer and more efficacious option for GN treatment.
引用
- Ma TK, McAdoo SP, Tam FW, et al. Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond. Nephrol Dial Transplant. 2017. PMID: 28391340. doi:10.1093/ndt/gfw336
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。